MONTREAL, Oct. 09, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company…
BEDFORD, Mass., Oct. 09, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), a biopharmaceutical company committed to improving…
Misetionamide-gemcitabine combination demonstrates very good safety profile and potential therapeutic benefit in the challenging treatment of pancreatic adenocarcinoma Interim results…
– Additional positive data from the Company’s completed Phase 1 clinical trial evaluating ENTR-601-44 reinforces its safety profile and supports…
Purespring Therapeutics raises £80/$105 million in a Series B financing to transform the treatment of kidney diseases Oversubscribed financing led…
WATERTOWN, Mass., Oct. 09, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to…
SAN FRANCISCO, Oct. 09, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted…
KT-621 has demonstrated dupilumab-like activity and was well tolerated ina wide variety of preclinical models of TH2 diseases KT-621 is…
Poster presentations include new preclinical data demonstrating activity for palazestrant in combination with capivasertib and everolimus, and OP-3136, Olema’s KAT6…
RAMAT GAN, Israel, Oct. 09, 2024 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company…